Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment to improve the lives of patients suffering from pruritus. The company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA and EMA approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The company is developing an…More oral formulation of difelikefalin for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease, atopic dermatitis, and notalgia paresthetica.
Cara Therapeutics Inc does not currently have any hardcopy reports on AnnualReports.co.uk. Click the button below to request a report when hardcopies become available.
Shipping Information
Please fill out the form below and click "Place Order" to complete your order.